Relay Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026More shares available means the company can raise money or pay people with stock, but existing shareholders own a smaller piece.
Company will raise about $258.5 million in cash by selling new shares to public investors through banks.
Company receives $258.5 million before costs; investors buying shares should understand their ownership will be diluted.
Preliminary document shows planned share sale details before final pricing; helps investors understand offering structure.
Drug development progress matters because successful trials can increase company value and help patients with rare conditions.
Quarterly earnings show if company is spending money wisely and making progress toward profitability.
Regular financial updates help investors track company performance and whether it's burning cash too quickly.
Stocky reads Relay Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Relay Therapeutics, Inc.'s most recent tracked filing was a 8-K on 9 Jun 2026: Stockholders approve share count increase to 450 million.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.